News
RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.
Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients
Business Development Manager Position Available
We’re #hiring. Know anyone who might be interested? Please feel free to share this information with others who may be interested.
Yuhan USA team attended NEBS 2024 32nd Annual Conference
Yuhan USA team attended NEBS 2024 32nd Annual Conference on May 18th at the Harvad Medical School. Yuhan is a proud sponsor of NEBS and it’s always
Yuhan USA to participate at 2024 BIO International Convention in June
Yuhan USA to participate at 2024 BIO International Convention in June Yuhan USA, a subsidiary of Yuhan Corporation, will be participating in 2024 BIO International
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein
‘Amivantamab’ and ‘Lazertinib’ Combination Treatment Shows Extended PFS as First-line of Therapy in NSCLC
Yuhan Corporation’s 3rd generation EGFR TKI, ‘Lazertinib’, has taken another step towards its global blockbuster aspirations.This achievement comes as a result of successful outcomes in